指南与共识淋巴瘤

成人伯基特淋巴瘤的诊断与治疗:ERN-EuroBloodNet临床实践指南

Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet.
指南 / 共识 · Lancet Haematol · 2025-01-01

伯基特淋巴瘤占成人淋巴瘤不足5%,预后随剂量密集治疗改善,但高肿瘤负荷患者中枢神经系统受累和肿瘤溶解综合征发生率高。ERN-EuroBloodNet专家小组由8个欧盟成员国的10名临床医生和病理学家组成,另设2名血液科医生支持系统评价,基于近期进展制定了一线诊疗的循证与专家意见推荐。

要点

  • 伯基特淋巴瘤占成人淋巴瘤不足5%,高肿瘤负荷者中枢神经系统受累和肿瘤溶解综合征发生率高。
  • 专家小组由8个欧盟成员国的10名临床医生和病理学家组成,另设2名血液科医生支持系统评价。
  • 指南提供诊断、风险适应一线治疗、肿瘤溶解综合征和中枢神经系统导向治疗及预后评估推荐。

核心结论

  • 专家小组基于近期进展制定了成人伯基特淋巴瘤诊断、风险适应一线治疗、重要并发症管理及预后评估的循证与专家意见推荐。

研究设计与样本

  • 欧洲罕见血液病参考网络(ERN-EuroBloodNet)专家小组由8个欧盟成员国的10名临床医生和病理学家组成。
  • 另设2名血液科医生支持系统评价过程,并确保与ERN-EuroBloodNet有关和无关人员之间的均衡代表性。

主要发现

  • 伯基特淋巴瘤是一种罕见淋巴瘤,占成人淋巴瘤不足5%。
  • 剂量密集治疗改善了预后,但高肿瘤负荷患者中枢神经系统受累和肿瘤溶解综合征发生率高。
  • 关于成人患者诊断、治疗和预后因素的共识推荐很少。

关键数值与推荐

  • 指南提供诊断和风险适应一线治疗的当前指征。
  • 指南包含肿瘤溶解综合征和中枢神经系统导向治疗等重要并发症识别与管理的具体推荐。
  • 指南包含用于指导治疗的预后评估推荐。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 关于成人患者诊断、治疗和预后因素的共识推荐很少。
  • 遗传学、影像学和二线治疗等方面仍存在未解决问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas. Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains an area of clinical and biological research with specificities due to the high incidence of CNS involvement and tumour lysis syndrome in patients with a high tumour burden. Few consensus recommendations are available concerning diagnosis, treatment, and prognostic factors in adult patients. In this Review, a European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet) expert panel has reviewed recent advances in the management of Burkitt lymphoma in the first-line setting to develop updated evidence-based and expert opinion-based recommendations on the management of this disease. The expert panel consisted of ten clinicians and pathologists involved in the clinical management of Burkitt lymphoma from eight EU member states. Additionally, two haematologists were included to support the systematic review process. A balanced representation was ensured between individuals affiliated and not affiliated with ERN-EuroBloodNet. Together with providing current indications on diagnosis and risk-adapted first-line therapy, the Review contains specific recommendations for the identification and management of important complications of Burkitt lymphoma such as tumour lysis syndrome and CNS-oriented therapy, and recommendations for prognostic assessment to guide treatment. Finally, unresolved questions for Burkitt lymphoma are highlighted, including questions around genetics, imaging, and second-line therapies, along with patient perspective.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Ribrag V, Bron D, Rymkiewicz G, et al. Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet. Lancet Haematol. 2025. PMID: 39909657. doi:10.1016/S2352-3026(24)00351-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。